NASDAQHealth CareSoftware - InfrastructureSnapshot 2026-07-31
Reading RKTO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Systems Software: fringe margins under pressure (2q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
RKTO's growth depends on the Healthcare sector's performance and momentum. If major companies like UNH, JNJ, and LLY keep beating earnings, RKTO may benefit. Revenue growth is uncertain as there is no recent earnings release on record. RKTO trades at a high risk level, and the market is sensitive to interest rates and inflation. If inflation rises above 3.5%, it could delay Fed rate cuts, negatively impacting RKTO. Peer multiples imply a price about 12% above where it trades; this read is provisional.
Trailing returns as of 2026-07-31. RKTO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-08-02. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus peers — fair value, gap to price, and forward P/E.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
